You are here:

Latest News

February 2017 decisions news release

Treatments for cancer, cholesterol and chronic migraines among medicines accepted for routine use by NHS Scotland. 

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today (Monday 13 February) published advice accepting six new medicines for routine use by NHS Scotland.
 

January 2017 decisions news release

Four new medicines accepted for routine use in Scotland

The Scottish Medicines Consortium (SMC) has today (Monday 16 January) published advice accepting four new medicines for routine use in NHS Scotland.

 

Review of Access to New Medicines Report

The Scottish Government has published Dr Brian Montgomery’s Review of Access to New Medicines, which assesses the impact of the new approach introduced in 2014 by SMC and sets out how the process for appraising medicines can be made even more open, transparent and robust.

 

December 2016 decisions news release

Treatment for advanced prostate cancer accepted for routine use 

The Scottish Medicines Consortium (SMC) has today (Monday 12 December) published advice accepting a medicine used to treat advanced prostate cancer for routine use by NHS Scotland. 

 

Updated submission form and guide for Patient Group Partners

Following feedback from patient groups and our committee members we have introduced an updated Patient Group submission form which will be used for all submissions from January 2017 onwards. 

 

November 2016 decisions news release

Five new medicines accepted for routine use in Scotland. 

The Scottish Medicines Consortium (SMC) has today (Monday 7 November) published advice accepting five new medicines for routine use in NHS Scotland. 
 

October 2016 decisions news release

New treatments for thyroid cancer and lung cancer among five medicines accepted for routine use by NHS Scotland. 

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today (Monday 10 October) published advice accepting five new medicines for routine use by NHS Scotland. Two of these medicines, lenvatinib (Lenvima) for advanced thyroid cancer and nivolumab (Opdivo) which can be used to treat a type of lung cancer, were accepted after consideration through the Patient and Clinician Engagement (PACE) process for medicines that treat end of life and very rare conditions.

 

Leading rheumatologist appointed new chair of SMC

Leading rheumatologist appointed next chair of Scottish Medicines Consortium. 

One of Scotland’s leading rheumatologists has been appointed as the next chair of the Scottish Medicines Consortium (SMC), the body which reviews newly licensed medicines for routine use by NHS Scotland.
 

September 2016 decisions news release

Three new medicines accepted for routine use by NHS Scotland

The Scottish Medicines Consortium (SMC) has today (Monday 12 September) published advice accepting three new medicines for routine use in NHS Scotland. 
 

Updated guidance on comparator medicines with a Patient Access Scheme

SMC submissions for products where the comparator medicine has been accepted for use on the basis of a confidential Patient Access Scheme (PAS).

SMC’s guidance to manufacturers about comparator medicines accepted for use on the basis of a confidential Patient Access Scheme (PAS) is changing. Find out more